1)藤原靖弘:GERD疫学—最近の動向.日消誌114:1781-1789, 2017
2)Ishikawa H, et al:Effect of nifedipine administration(10 mg)on esophageal acid exposure time. J Gastroenterol 35:43-46, 2000
3)富田詩織:GERDにおける一般的な診療評価指標.medicina 59:1986-1990, 2022
4)日本消化器病学会(編):胃食道逆流症(GERD)診療ガイドライン2021 改訂第3版,南江堂,2021
5)Miyazaki H, et al:Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease;A systematic review. J Gastroenterol Hepatol 34:1316-1328, 2019
6)Yokoya Y, et al:Cost-utility analysis of a ‘vonoprazan-first’ strategy versus ‘esomeprazole- or rabeprazole-first’ strategy in GERD. J Gastroenterol 54:1083-1095, 2019
7)Adachi K:Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J Gastroenterol Hepatol 16:1191-1196, 2001
8)Carlsson R, et al:Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs;A meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 11:473-482, 1997
9)Fujimoto K, Hongo M:Risk factors for relapse of erosive GERD during long-term maintenance treatment with proton pump inhibitor;A prospective multicenter study in Japan. J Gastroenterol 45:1193-1200, 2010
10)Lauristen K, et al:Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis;Metropole study results. Aliment Pharmacol Ther 17:333-341, 2003
11)Kinoshita Y, et al:Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor;The Japan-based EXTEND study. J Gastroenterol 53:834-844, 2018
12)Ashida K, et al:Maintenance for healed erosive esophagitis;Phase Ⅲ comparison of vonoprazan with lansoprazole. World J Gastroenterol 14:1550-1561, 2018